BioNTech, Ryvu collaborate on small molecule immuno-modulatory therapies
Under the collaboration, the two companies will jointly develop several small molecule programmes, primarily targeting immune modulation in…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
01 Dec 22
Under the collaboration, the two companies will jointly develop several small molecule programmes, primarily targeting immune modulation in…
30 Nov 22
The transaction consideration includes an initial payment of $200m upon closing, and contingent milestones-based and non-contingent consideration of…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
29 Nov 22
AstraZeneca will develop and market an oral therapy for the treatment of inflammatory and respiratory diseases with focus…
28 Nov 22
The Taiwan Food and Drug Administration has granted accelerated approval designation (AAD), and South Korea’s Ministry of Food…
28 Nov 22
The South Korean biotech firm claimed that the anticancer therapy candidate could complete chemotherapy with two doses in…
25 Nov 22
The two-dose vaccine, which leverages the same mRNA technology used in the Covid-19 vaccines developed by Pfizer and…
24 Nov 22
Skyrizi is a humanised monoclonal antibody inhibitor that selectively targets interleukin-23 (IL-23), a cytokine involved in inflammatory processes,…
23 Nov 22
Hemgenix is a gene therapy that promotes continuous production of factor IX to reduce abnormal bleeding in people…
22 Nov 22
Merck, through its acquisition subsidiary, will initiate a tender offer to acquire all outstanding shares of Imago for…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Nov 22
The expanded approval adds new dosing options for Rylaze, which provides sustained asparaginase activity for adult and paediatric…